Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (141-150 of 189) with videos related to

Pageof 19
Sort By:
Journal for Immunotherapy of Cancer|January 17, 2023
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myelomaRong Fan, Hatice Satilmis, Niels Vandewalle, et al.
British Journal of Haematology|March 13, 2020
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group modelRoman Hájek, Viera Sandecka, Ivan Špička, et al.
British Journal of Cancer|March 4, 2018
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsAngelique Bruyer, Ken Maes, Laurie Herviou, et al.
Blood|April 23, 2013
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.
Frontiers in Immunology|November 30, 2023
RNA-sequencing based first choice of treatment and determination of risk in multiple myelomaMartina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
JCI Insight|April 20, 2018
Antigen-mediated regulation in monoclonal gammopathies and myelomaShiny Nair, Joel Sng, Chandra Sekhar Boddupalli, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Pageof 19

Showing results (141-150 of 189) with videos related to

Sort By:
Pageof 19
Journal for Immunotherapy of Cancer|January 17, 2023
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myelomaRong Fan, Hatice Satilmis, Niels Vandewalle, et al.
British Journal of Haematology|March 13, 2020
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group modelRoman Hájek, Viera Sandecka, Ivan Špička, et al.
British Journal of Cancer|March 4, 2018
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsAngelique Bruyer, Ken Maes, Laurie Herviou, et al.
Blood|April 23, 2013
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.
Frontiers in Immunology|November 30, 2023
RNA-sequencing based first choice of treatment and determination of risk in multiple myelomaMartina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
JCI Insight|April 20, 2018
Antigen-mediated regulation in monoclonal gammopathies and myelomaShiny Nair, Joel Sng, Chandra Sekhar Boddupalli, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Pageof 19